Program
Rivaroxaban
Also written as “Rivaroxaban (Xarelto, BAY59-7939)”, “Xarelto (Rivaroxaban, BAY59-7939)” and “Rivaroxaban (BAY59-7939)”.
Its studies are mostly in Venous Thromboembolism · Atrial Fibrillation · Venous Thrombosis · Thrombosis · Pulmonary Embolism, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 450 open or running | phase 3since May 24, 2006 | May 24, 2006 | none ahead |
| Johnson & Johnson | 170 open or running | phase 4since Sep 11, 2015 | Nov 21, 2006 | none ahead |
| Dexa Medica Group | 20 open or running | phase 1since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| Pharmtechnology | 20 open or running | phase 1since Jan 25, 2021 | Jan 25, 2021 | none ahead |
| ECRI bv | 10 open or running | phase 3since Jun 24, 2016 | Jun 24, 2016 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Mar 1, 2017 | Mar 1, 2017 | none ahead |
| Merck | 10 open or running | phase 1since Jun 3, 2011 | Jun 3, 2011 | none ahead |
| pharmevo-pvt-ltd | 10 open or running | phase 4since Dec 8, 2016 | Dec 8, 2016 | none ahead |
| Yuhan | 10 open or running | phase 1since Nov 10, 2021 | Nov 10, 2021 | none ahead |
Also a collaborator on its studies: parexel, pt-equilab-international and cardialysis-bv.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Feb 23, 2007.
- Sep 4, 2015Phase 2 study in ThromboembolismBayer · NCT02564718 · 10 enrolled · Austria, France, Germany and more
- Sep 5, 2015Phase 3 study in Transcatheter Aortic Valve ReplacementBayer · NCT02556203 · 1,653 enrolled · United States, Austria, Belgium and more
- Sep 11, 2015Phase 4 study in Pulmonary EmbolismJohnson & Johnson · NCT02584660 · 114 enrolled · United States
- Sep 18, 2015Phase 3 study in NeoplasmsJohnson & Johnson · NCT02555878 · 841 enrolled · United States, Belgium, Brazil and more
- Jun 24, 2016ECRI bv's first study: phase 3 study in Aortic Valve StenosisNew to ECRI bvECRI bv · NCT02833948 · 231 enrolled · United States, Canada, Denmark and more
- Jul 25, 2016Phase 3 study in ThrombosisJohnson & Johnson · NCT02846532 · 112 enrolled · United States, Argentina, Belgium and more
- Dec 8, 2016pharmevo-pvt-ltd's first study: phase 4 study in Mitral Valve StenosisNew to pharmevo-pvt-ltdpharmevo-pvt-ltd · NCT03673605 · Pakistan
- Mar 1, 2017Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT03071380 · 24 enrolled · Egypt
- Aug 10, 2020Phase 3 study in COVID-19Johnson & Johnson · NCT04508023 · 1,284 enrolled · United States
- Jan 19, 20212 phase 1 studiesBayer · NCT04727021, NCT04720092
- Jan 25, 2021Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT04729998 · 34 enrolled · Russian Federation
- Feb 10, 2021Phase 1 study in BioequivalencePharmtechnology · NCT04753489 · 34 enrolled · Russian Federation
- Nov 10, 2021Yuhan's first study: phase 1 study in Embolism and ThrombosisNew to YuhanYuhan · NCT05128591 · 38 enrolled · Korea, Republic of
- Aug 14, 2024Dexa Medica Group's first studies: 2 phase 1 studies in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT06558058, NCT06558045
TargetBeta
“Coagulation factor X inhibitor”ChEMBL 37, by rule
Other programs on F10
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| apixabanrule | Bristol-Myers Squibb | phase 4 | 44 |
| emicizumabrule | Hoffmann-La Roche | phase 4 | 13 |
| Factor Xrule | kedrion-s-p-a | phase 3 | 1 |
Studies
The newest 60 of 71 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06558058Healthy · Indonesia | 1 | Completed | Dexa Medica Group | Jun 16, 2023 | 28 |
| NCT06558045Healthy · Indonesia | 1 | Completed | Dexa Medica Group | Jul 18, 2023 | 26 |
| NCT05128591Embolism and Thrombosis · Korea, Republic of | 1 | Completed | Yuhan | Dec 31, 2021 | 38 |
| NCT04753489Bioequivalence · Russian Federation | 1 | UNKNOWN | Pharmtechnology | Mar 1, 2021 | 34 |
| NCT04729998Bioequivalence · Russian Federation | 1 | UNKNOWN | Pharmtechnology | Feb 15, 2021 | 34 |
| NCT04720092Thromboembolism · Germany | 1 | Completed | Bayer | Aug 28, 2017 | 30 |
| NCT04727021Healthy Volunteers · Germany | 1 | Completed | Bayer | Sep 4, 2017 | 30 |
| NCT04508023COVID-19 · United States | 3 | Terminated | Johnson & Johnson | Jun 1, 2022 | 1,284 |
| NCT03071380Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Feb 2015 | 24 |
| NCT03673605Mitral Valve Stenosis · Pakistan | 4 | Withdrawn | pharmevo-pvt-ltd | Oct 30, 2017 | 0 |
| NCT02846532Thrombosis · United States, Argentina, Belgium and more | 3 | Completed | Johnson & Johnson | Jul 16, 2020 | 112 |
| NCT02833948Aortic Valve Stenosis · United States, Canada, Denmark and more | 3 | Completed | ECRI bv | Dec 2018 | 231 |
| NCT02555878Neoplasms · United States, Belgium, Brazil and more | 3 | Completed | Johnson & Johnson | Aug 24, 2018 | 841 |
| NCT02584660Pulmonary Embolism · United States | 4 | Completed | Johnson & Johnson | Mar 22, 2017 | 114 |
| NCT02556203Transcatheter Aortic Valve Replacement · United States, Austria, Belgium and more | 3 | Terminated | Bayer | Nov 27, 2018 | 1,653 |
| NCT02564718Thromboembolism · Austria, France, Germany and more | 2 | Completed | Bayer | Dec 18, 2017 | 10 |
| NCT02537457Embolism · Japan | 1 | Completed | Bayer | Mar 2014 | 40 |
| NCT02537405Embolism · Japan | 1 | Completed | Bayer | Mar 2014 | 40 |
| NCT02561923Healthy · United States | 1 | Completed | Johnson & Johnson | Jun 17, 2016 | 158 |
| NCT02504216Peripheral Arterial Disease · United States, Argentina, Austria and more | 3 | Completed | Bayer | Nov 27, 2019 | 6,564 |
| NCT02497716Thrombosis · United States, Belgium, Canada and more | 1 | Completed | Bayer | May 22, 2018 | 47 |
| NCT02367027Pharmacokinetics · Germany | 1 | Completed | Bayer | Apr 2015 | 18 |
| NCT02313909Stroke · United States, Argentina, Australia and more | 3 | Terminated | Bayer | Feb 15, 2018 | 7,213 |
| NCT02309411Venous Thromboembolism · United States, Australia, Austria and more | 2 | Completed | Bayer | Apr 5, 2017 | 46 |
| NCT02293395Acute Coronary Syndrome · United States, Argentina, Australia and more | 2 | Completed | Johnson & Johnson | Oct 14, 2016 | 3,037 |
| NCT02289703Kidney Failure, Chronic · United States | 1 | Completed | Johnson & Johnson | Mar 2015 | 16 |
| NCT02234843Venous Thromboembolism · United States, Argentina, Australia and more | 3 | Completed | Bayer | Jan 30, 2019 | 500 |
| NCT02111564Heart Failure · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Mar 6, 2018 | 12,024 |
| NCT02064439Pulmonary Embolism · United States, Australia, Austria and more | 3 | Completed | Bayer | Sep 22, 2016 | 3,365 |
| NCT01877915Heart Failure · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Apr 19, 2018 | 5,081 |
| NCT01853800Biological Availability · Germany | 1 | Completed | Bayer | Jul 2013 | 14 |
| NCT01839357Atrial Fibrillation · Bulgaria, France, Germany and more | 3 | Completed | Bayer | Nov 2014 | 60 |
| NCT01830543Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Jul 28, 2016 | 2,124 |
| NCT01776424Coronary Artery Disease · United States, Argentina, Australia and more | 3 | Completed | Bayer | Jul 21, 2017 | 27,395 |
| NCT01729871Atrial Fibrillation · United States, Belgium, France and more | 3 | Completed | Johnson & Johnson | Oct 2014 | 253 |
| NCT01684423Venous Thrombosis · United States, Australia, Austria and more | 2 | Completed | Bayer | Sep 1, 2016 | 64 |
| NCT01674647Atrial Fibrillation · United States, Belgium, Brazil and more | 3 | Completed | Bayer | Jan 2014 | 1,504 |
| NCT01516840Venous Thrombosis · Japan | 3 | Completed | Bayer | Dec 2013 | 60 |
| NCT01516814Pulmonary Embolism · Japan | 3 | Completed | Bayer | Oct 2013 | 40 |
| NCT01507051Venous Thrombosis · Germany | 1 | Completed | Bayer | Nov 2009 | 96 |
| NCT01464450Pharmacokinetics · United States | 1 | Completed | Johnson & Johnson | Dec 2011 | 55 |
| NCT01436526Therapeutic Equivalency · Germany | 1 | Completed | Bayer | Sep 2009 | 28 |
| NCT01442792Cardiovascular Diseases · Belgium, Netherlands | 2 | Completed | Bayer | Jan 29, 2013 | 108 |
| NCT01379300Thrombosis | 1 | Completed | Merck | Dec 2011 | 42 |
| NCT01309438Renal Insufficiency · United States | 1 | Completed | Johnson & Johnson | Mar 2012 | 29 |
| NCT01206972Venous Thromboembolism · Japan | 3 | Completed | Bayer | May 2011 | 302 |
| NCT01205932Venous Thromboembolism · Japan | 3 | Completed | Bayer | Jun 2011 | 402 |
| NCT01145859Venous Thrombosis · United States, Australia, Austria and more | 1 | Completed | Bayer | Jul 2015 | 59 |
| NCT01094886Arthritis · United States | 3 | Completed | Johnson & Johnson | Dec 2010 | 56 |
| NCT00973245Atrial Fibrillation · Japan | 2 | Completed | Bayer | 102 | |
| NCT00973323Atrial Fibrillation · Japan | 2 | Completed | Bayer | 100 | |
| NCT00839826Thromboembolism · Austria, Belgium, Denmark and more | 2 | Completed | Bayer | Nov 2003 | 641 |
| NCT00839163Venous Thrombosis · Australia, Austria, Belgium and more | 2 | Completed | Bayer | Oct 2005 | 613 |
| NCT00809965Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Sep 2011 | 15,526 |
| NCT00786422Venous Thrombosis · Australia, Austria, Brazil and more | 2 | Completed | Bayer | May 2011 | 25 |
| NCT00779064Atrial Fibrillation · Japan | 2 | Completed | Bayer | Jun 2005 | 36 |
| NCT00571649Venous Thromboembolism · United States, Argentina, Australia and more | 3 | Completed | Bayer | Aug 2010 | 8,101 |
| NCT00494871Atrial Fibrillation · Japan | 3 | Completed | Bayer | Dec 2009 | 1,280 |
| NCT00440193Venous Thrombosis · United States, Australia, Austria and more | 3 | Completed | Bayer | Apr 2010 | 3,449 |
| NCT00439777Pulmonary Embolism · United States, Andorra, Australia and more | 3 | Completed | Bayer | Sep 2011 | 4,833 |
How it is read
Names in the registry
- “Rivaroxaban (Xarelto, BAY59-7939)”, 46 entries
- “Rivaroxaban”, 14 entries
- “Xarelto (Rivaroxaban, BAY59-7939)”, 13 entries
- “Rivaroxaban (BAY59-7939)”, 13 entries
- “Rivaroxaban, (BAY59-7939)”, 3 entries
Conditions, from the studies’ own filings
- Venous Thromboembolism, 14 studies
- Atrial Fibrillation, 9 studies
- Venous Thrombosis, 7 studies
- Thrombosis, 4 studies
- Pulmonary Embolism, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.